Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 37, Issue 11, Pages 887-903Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2016.09.003
Keywords
-
Categories
Funding
- National Health and Family Planning Commission of PRC [201402031]
Ask authors/readers for more resources
Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, survival, and quality of life. However, acquired resistance to EGFR-TKIs is inevitable. Ongoing clinical trials will provide evidence for optimal strategies for patients with EGFR mutant non-small-cell lung cancer (NSCLC) in the near future. Numerous new agents are specifically addressing resistance mechanisms; mature data are related to the T790M mutation and MET pathway activation. Here, we provide a comprehensive review of new perspectives on how to optimize the management of this molecular disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available